219:: A substrate is added to the wells, and is catalyzed by the enzyme conjugate added in the previous step. This reaction forms insoluble precipitate that forms spots in the wells. The substrate that you use in this step will depend on the type of enzyme used in the previous step. If streptavidin-ALP (streptavidin and alkaline phosphatase conjugate) is used, then using BCIP/NBT-plus (a mixture of 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium chloride) as a substrate will produce more distinct spots that are easier to analyze. If streptavidin-HRP (streptavidin and horseradish peroxidase conjugate) is used, then using TMB (tetramethylbenzidine) as a substrate will produce better results.
246:: Similar to the ELISpot, cytokine-specific monoclonal capture antibodies are added to a plate with wells. For both assays, the plates are ethanol-treated to avoid contamination and skewed data collection. For the FluoroSpot assay, a mixture of different types of capture antibodies are attached to the wells in order to detect multiple types of analytes. In order to get optimal results with the ELISpot and the FluoroSpot assay, proper plate coating techniques should be followed. The plates should be treated with ethanol, washed, and then coated with antibodies.
169:: The desired cells being observed and analyzed are added to the wells. Each well can have the presence or absence of stimuli that activate the secretion of cytokine in cells. During cell incubation, the cells are allowed to react to any present stimuli and secrete cytokine. There are many procedures and methods to follow to ensure proper cell handling. To make sure that cells are of high quality, cells in blood samples should be lightly agitated if stored for longer than 3 hours, the blood samples should be diluted in PBS (
33:
149:: Throughout the ELISpot Assay technique, different substances are added to and washed away from wells. Wells are found on a laboratory plate with tiny dishes/bowls that can be filled with a substance to be examined; the amount of wells on a plate varies, but it usually ranges from 16-100. The first substance added to the wells are cytokine specific monoclonal antibodies. These antibodies coat the walls of the wells for future binding to cytokine. The
251:
liters of 70% ethanol to all of the wells. Allow the ethanol to sit in the wells for two minutes, and then pour it out. After you have treated the wells with ethanol, you need to wash all of the wells with 200 micro liters of sterile water. This washing process should be repeated for a total of 5 times. Once the wells have been treated with ethanol and washed, the cytokine-specific monoclonal capture antibodies can be added to each well.
211:: Streptavidin-enzyme conjugate is added to the wells in order to bind with the detection antibodies. The purpose of biotinylating the cytokine-specific detection antibodies added to the wells in the previous step is so that the antibody can bind to the new streptavidin-enzyme conjugate. Biotinylation basically creates a strong affinity between the biotin on the cytokine-specific antibody and the streptavidin on the conjugate.
296:: Since the FluoroSpot relies on the use of fluorescence and not an enzymatic reaction, there is no need for a step that adds a substrate to react with enzymes (as needed for the ELISpot). The last step for the FluoroSpot assay is to analyze the fluorophores under an automated fluorescence reader that has separate filters for the different fluorophores being analyzed. These filters should be selected for the specific
275:: Similar to the ELISpot, once the wells are rinsed to get rid of the cells and other substances that we are not interested in identifying or measuring, a biotinylated detection antibody is added (this is specific for one type of analyte that you wish to quantify) and then tag-labeled detection antibodies are added for the second and third types of analytes being studied.
305:
production of the second analyte can either increase or decrease). To counteract capture effects, it is possible to use co-stimulation in order to bypass the decreased production of an analyte. This is when a second antibody that stimulates the production of the same analyte is added to the wells.
181:
and thawed should be allowed to rest for an hour or more at 37 degrees
Celsius (the typical temperature of the human body). There are also many things that should be taken into consideration when incubating the cells, such as making sure that the cells do not experience sudden movements that could
236:
The FluoroSpot assay is very similar to the ELISpot assay. The main difference is that the FluoroSpot assay is able to analyze the presence of multiple analytes on one plate of wells, whereas the ELISpot assay can only analyze one analyte at a time. The FluoroSpot assay accomplishes this by using
317:
More specifically, the T-cell ELISpot assay is used to characterize T-cell subsets. This is because the assay can detect the production of cytokines IFN-y, IL-2, TNF-alpha, IL-4, IL-5, and IL-13. The first three cytokines are produced by Th1 cells, while the last three are produced by Th2 cells.
313:
The ELISpot and FluoroSpot assays can be used in many research fields: vaccine development, cancer, allergies, monocytes/macrophages/dendritic cells characterization, apolipoproteins analysis, and veterinary research. With the ELISpot, you can study antigen-specific cytokine responses, antibody
250:
treatment methods also vary depending on the type of plates that are used. For MSIP and IPFL plates, you should add 15 micro liters of 35% ethanol to all of the wells. Allow the ethanol to sit in the wells for one minute, and then pour it out. For MAIPSWU plates, you should instead add 50 micro
202:
cytokine-specific detection antibodies are then added to the well. These cytokine-specific detection antibodies will bind to any cytokine that is left in the well since the cytokine is still attached to the first set of antibodies used. Since the cytokine attached to the first set of antibodies
304:
Since the FluoroSpot assay identifies and quantifies the presence of multiple analytes, it is possible that the absorption of one analyte can affect the secretion of another analyte; this is called capture effects. The effect an analyte has on another analyte could be positive or negative (the
314:
specific secreting cells, tumor antigens, granzyme B and
Perforin release by T cells, vaccine efficacy, epitope mapping, cytotoxic T-cell activity, detection of IL-4, IL-5, and IL-13, vaccine-induced antibody responses, antigen-specific memory B cells, and much more.
287:
enhancer solution is also added during this step in order to enhance the signals later used when analyzing the fluorescence colors in the wells. This fluorescence is what makes it possible for the FluoroSpot to analyze and compare multiple analytes, unlike the
135:. In the same year, dual-color ELISpot was combined with computer imaging for the first time, which allowed for the enumeration and analysis of spots. 1988 also marked the first use of membrane-bottomed plates for performing these assays.
198:: At this point, the wells must be rinsed in order to get rid of the cells and any other undesirable substances. All that should remain are the cytokine specific monoclonal antibodies and any cytokine that bonded to the antibodies.
321:
With T-cell FluoroSpot, you can monitor tumor-infiltrating lymphocytes. You can also analyze the IFN-y cytokine and granzyme B secretion in order to assess cytotoxic T-cell responses. Both of these are used for cancer research.
190:: Since the cells are surrounded by cytokine specific monoclonal antibodies that coat the walls of the wells, cytokine that has been secreted by the incubated cells will start to attach to the antibodies at a specific epitope.
283:: Instead of adding a streptavidin-enzyme conjugate, the detection of multiple analytes is amplified in the FluoroSpot with the use of fluorophore-labeled anti-tag antibody and streptavidin-fluorophore conjugate. A
437:
866:
227:: The spots that are formed can then be read on an automated ELISpot reader, or counted under a dissection microscope, and further used to calculate the frequency of cytokine secretion.
325:
With B-cell FluoroSpot, vaccine efficacy can also be observed by quantifying the secretion of IgG, IgA, and IgM before and after a vaccination. This analysis of multiple
859:
719:
Saletti, Giulietta (9 May 2013). "Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood".
852:
960:
684:
Czerkinsky, CC (16 December 1983). "A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells".
387:
363:
267:: Proteins/analytes that are secreted by the incubated cells will bind to the capture antibodies attached to the wells during the first step.
518:
237:
fluorescence rather than an enzymatic reaction for detection. The steps for a FluoroSpot assay are also similar, with a few differences.
910:
67:
104:
to detect a protein analyte, with the word analyte referring to any biological or chemical substance being identified or measured.
412:
119:
Cecil
Czerkinsky first described ELISpot in 1983 as a new way to quantify the production of an antigen-specific immunoglobulin by
52:
Please help improve this article by looking for better, more reliable sources. Unreliable citations may be challenged and removed.
182:
affect spot formation, or that the incubator's humidity is high enough to avoid excessive evaporation and drying out the wells.
883:
1103:
900:
46:
945:
925:
575:
550:
1055:
41:
259:: Cell are added to the wells and are incubated in the presence or absence of stimuli that affect protein secretion.
1108:
1077:
170:
603:
1040:
965:
111:
in order to analyze multiple analytes, meaning it can detect the secretion of more than one type of protein.
990:
915:
32:
462:
318:
Measuring T-cell responses through cytokine production also makes it possible to study vaccine efficacy.
1030:
920:
158:
153:
means that the antibody is produced from a single cell lineage, and is only able to bind to one protein
820:
1050:
844:
490:
120:
659:
1045:
1014:
892:
788:
631:
150:
980:
975:
744:
161:
antibodies, on the other hand, are capable of binding to multiple epitopes of the same protein.
1067:
736:
701:
369:
359:
998:
970:
762:
728:
693:
351:
178:
1062:
905:
326:
97:
1097:
1002:
697:
199:
748:
107:
The FluoroSpot Assay is a variation of the ELISpot assay. The FluoroSpot Assay uses
1035:
875:
284:
108:
346:
Ranieri, Elena; Popescu, Iulia; Gigante, Margherita (2014). "CTL ELISPOT Assay".
1007:
937:
355:
174:
203:
coating the wells, the cytokine was not washed away when the wells were rinsed.
1072:
879:
297:
128:
17:
329:
is made possible because of the fluorescence method used in the FluoroSpot.
740:
732:
373:
705:
101:
93:
247:
154:
1082:
132:
950:
124:
89:
96:
secretion for a single cell. The ELISpot Assay is also a form of
350:. Methods in Molecular Biology. Vol. 1186. pp. 75–86.
848:
26:
173:) before being stored, and the blood samples should not have
92:
that focuses on quantitatively measuring the frequency of
300:
of the fluorophores if you want accurate measurements.
1023:
989:
936:
891:
100:since it is classified as a technique that uses
127:spot assay that quantified the secretion of a
860:
8:
867:
853:
845:
68:Learn how and when to remove this message
961:Enzyme multiplied immunoassay technique
338:
309:Applications of ELISpot and FluoroSpot
814:
812:
789:"Find 1 cell in 100,000 with ELISpot"
654:
652:
626:
624:
598:
596:
7:
545:
543:
541:
539:
123:. In 1988, Czerkinsky developed an
911:Ouchterlony double immunodiffusion
388:"Cells for ELISpot and FluoroSpot"
25:
686:Journal of Immunological Methods
82:enzyme-linked immunosorbent spot
31:
821:"Discover more with FluoroSpot"
280:Fluorophore-labeled Conjugates
1:
901:Chromatin immunoprecipitation
208:Streptavidin-enzyme conjugate
946:Chemiluminescent immunoassay
926:Counterimmunoelectrophoresis
698:10.1016/0022-1759(83)90308-3
551:"FluoroSpot Assay Principle"
1056:Direct fluorescent antibody
463:"BCIP/NBT-plus SDS Summary"
356:10.1007/978-1-4939-1158-5_6
177:. Any cells that have been
1125:
1078:Total complement activity
171:phosphate buffered saline
1041:Complement fixation test
491:"TMB Datasheet/Protocol"
763:"T cell ELISpot Assays"
442:ThermoFisher Scientific
232:Mechanism of FluoroSpot
40:Some of this article's
916:Radial immunodiffusion
733:10.1038/nprot.2013.058
1031:Diagnostic immunology
921:Immunoelectrophoresis
604:"Vaccine Development"
576:"Plate Coating Guide"
216:Addition of substrate
151:monoclonal antibodies
1104:Biochemistry methods
1051:Immunohistochemistry
519:"ELISpot Substrates"
272:Detection Antibodies
195:Detection antibodies
139:Mechanism of ELISpot
1046:Immunocytochemistry
1015:Latex fixation test
893:Immunoprecipitation
981:Immunofluorescence
976:Radiobinding assay
1109:Immunologic tests
1091:
1090:
1068:Skin allergy test
413:"Cell Incubation"
365:978-1-4939-1157-8
348:Cytotoxic T-Cells
78:
77:
70:
16:(Redirected from
1116:
999:Hemagglutination
971:Radioimmunoassay
869:
862:
855:
846:
839:
838:
836:
834:
825:
816:
807:
806:
804:
802:
793:
784:
778:
777:
775:
773:
759:
753:
752:
727:(6): 1073–1087.
721:Nature Protocols
716:
710:
709:
692:(1–2): 109–121.
681:
675:
674:
672:
670:
656:
647:
646:
644:
642:
628:
619:
618:
616:
614:
600:
591:
590:
588:
586:
572:
566:
565:
563:
561:
547:
534:
533:
531:
529:
515:
509:
508:
506:
504:
495:
487:
481:
480:
478:
476:
467:
459:
453:
452:
450:
448:
434:
428:
427:
425:
423:
409:
403:
402:
400:
398:
384:
378:
377:
343:
264:Cytokine Capture
243:Antibody Coating
187:Cytokine capture
146:Antibody coating
73:
66:
62:
59:
53:
35:
27:
21:
1124:
1123:
1119:
1118:
1117:
1115:
1114:
1113:
1094:
1093:
1092:
1087:
1063:Epitope mapping
1019:
985:
932:
906:Immunodiffusion
887:
873:
843:
842:
832:
830:
823:
819:Strand, Nacka.
818:
817:
810:
800:
798:
791:
787:Strand, Nacka.
786:
785:
781:
771:
769:
761:
760:
756:
718:
717:
713:
683:
682:
678:
668:
666:
658:
657:
650:
640:
638:
630:
629:
622:
612:
610:
602:
601:
594:
584:
582:
574:
573:
569:
559:
557:
549:
548:
537:
527:
525:
517:
516:
512:
502:
500:
493:
489:
488:
484:
474:
472:
465:
461:
460:
456:
446:
444:
438:"Biotinylation"
436:
435:
431:
421:
419:
411:
410:
406:
396:
394:
386:
385:
381:
366:
345:
344:
340:
335:
327:immunoglobulins
311:
256:Cell Incubation
234:
166:Cell incubation
141:
121:hybridoma cells
117:
88:) is a type of
74:
63:
57:
54:
51:
36:
23:
22:
15:
12:
11:
5:
1122:
1120:
1112:
1111:
1106:
1096:
1095:
1089:
1088:
1086:
1085:
1080:
1075:
1070:
1065:
1060:
1059:
1058:
1048:
1043:
1038:
1033:
1027:
1025:
1021:
1020:
1018:
1017:
1012:
1011:
1010:
995:
993:
987:
986:
984:
983:
978:
973:
968:
963:
958:
953:
948:
942:
940:
934:
933:
931:
930:
929:
928:
923:
918:
913:
903:
897:
895:
889:
888:
874:
872:
871:
864:
857:
849:
841:
840:
808:
779:
754:
711:
676:
648:
620:
592:
567:
535:
510:
482:
454:
429:
404:
379:
364:
337:
336:
334:
331:
310:
307:
302:
301:
289:
276:
268:
260:
252:
233:
230:
229:
228:
220:
212:
204:
191:
183:
162:
140:
137:
116:
113:
98:immunostaining
76:
75:
42:listed sources
39:
37:
30:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1121:
1110:
1107:
1105:
1102:
1101:
1099:
1084:
1081:
1079:
1076:
1074:
1071:
1069:
1066:
1064:
1061:
1057:
1054:
1053:
1052:
1049:
1047:
1044:
1042:
1039:
1037:
1034:
1032:
1029:
1028:
1026:
1022:
1016:
1013:
1009:
1006:
1005:
1004:
1003:Hemagglutinin
1000:
997:
996:
994:
992:
991:Agglutination
988:
982:
979:
977:
974:
972:
969:
967:
964:
962:
959:
957:
954:
952:
949:
947:
944:
943:
941:
939:
935:
927:
924:
922:
919:
917:
914:
912:
909:
908:
907:
904:
902:
899:
898:
896:
894:
890:
885:
881:
877:
876:Medical tests
870:
865:
863:
858:
856:
851:
850:
847:
829:
822:
815:
813:
809:
797:
790:
783:
780:
768:
764:
758:
755:
750:
746:
742:
738:
734:
730:
726:
722:
715:
712:
707:
703:
699:
695:
691:
687:
680:
677:
665:
661:
655:
653:
649:
637:
633:
627:
625:
621:
609:
605:
599:
597:
593:
581:
577:
571:
568:
556:
552:
546:
544:
542:
540:
536:
524:
520:
514:
511:
499:
492:
486:
483:
471:
464:
458:
455:
443:
439:
433:
430:
418:
414:
408:
405:
393:
389:
383:
380:
375:
371:
367:
361:
357:
353:
349:
342:
339:
332:
330:
328:
323:
319:
315:
308:
306:
299:
295:
294:
290:
286:
282:
281:
277:
274:
273:
269:
266:
265:
261:
258:
257:
253:
249:
245:
244:
240:
239:
238:
231:
226:
225:
221:
218:
217:
213:
210:
209:
205:
201:
197:
196:
192:
189:
188:
184:
180:
179:cryopreserved
176:
172:
168:
167:
163:
160:
156:
152:
148:
147:
143:
142:
138:
136:
134:
130:
126:
122:
114:
112:
110:
105:
103:
99:
95:
91:
87:
83:
72:
69:
61:
58:December 2018
49:
48:
43:
38:
34:
29:
28:
19:
18:ELISpot Assay
1036:Nephelometry
955:
886:86000–86849)
831:. Retrieved
827:
799:. Retrieved
795:
782:
770:. Retrieved
766:
757:
724:
720:
714:
689:
685:
679:
667:. Retrieved
663:
639:. Retrieved
635:
611:. Retrieved
607:
583:. Retrieved
579:
570:
558:. Retrieved
554:
526:. Retrieved
522:
513:
501:. Retrieved
497:
485:
473:. Retrieved
469:
457:
445:. Retrieved
441:
432:
420:. Retrieved
416:
407:
395:. Retrieved
391:
382:
347:
341:
324:
320:
316:
312:
303:
292:
291:
285:fluorescence
279:
278:
271:
270:
263:
262:
255:
254:
242:
241:
235:
223:
222:
215:
214:
207:
206:
200:Biotinylated
194:
193:
186:
185:
175:granulocytes
165:
164:
145:
144:
118:
109:fluorescence
106:
85:
81:
79:
64:
55:
44:
1008:Coombs test
938:Immunoassay
298:wavelengths
45:may not be
1098:Categories
1073:Patch test
880:immunology
833:6 December
801:6 December
772:6 December
669:6 December
641:6 December
613:6 December
585:6 December
560:6 December
528:6 December
503:6 December
475:6 December
447:6 December
422:6 December
397:6 December
333:References
159:Polyclonal
129:lymphokine
102:antibodies
966:RAST test
767:PROIMMUNE
660:"Allergy"
878:used in
749:38317207
741:23660756
632:"Cancer"
374:25149304
293:Analysis
288:ELISpot.
224:Analysis
94:cytokine
47:reliable
956:ELISpot
828:MABTECH
796:MABTECH
706:6361139
664:MABTECH
636:MABTECH
608:MABTECH
580:MABTECH
555:MABTECH
523:MABTECH
498:MABTECH
470:MABTECH
417:MABTECH
392:MABTECH
248:Ethanol
155:epitope
133:T cells
115:History
86:ELISpot
1083:MELISA
747:
739:
704:
372:
362:
1024:Other
951:ELISA
824:(PDF)
792:(PDF)
745:S2CID
494:(PDF)
466:(PDF)
125:ELISA
90:assay
835:2018
803:2018
774:2018
737:PMID
702:PMID
671:2018
643:2018
615:2018
587:2018
562:2018
530:2018
505:2018
477:2018
449:2018
424:2018
399:2018
370:PMID
360:ISBN
80:The
884:CPT
729:doi
694:doi
352:doi
131:by
1100::
826:.
811:^
794:.
765:.
743:.
735:.
723:.
700:.
690:65
688:.
662:.
651:^
634:.
623:^
606:.
595:^
578:.
553:.
538:^
521:.
496:.
468:.
440:.
415:.
390:.
368:.
358:.
157:.
1001:/
882:(
868:e
861:t
854:v
837:.
805:.
776:.
751:.
731::
725:8
708:.
696::
673:.
645:.
617:.
589:.
564:.
532:.
507:.
479:.
451:.
426:.
401:.
376:.
354::
84:(
71:)
65:(
60:)
56:(
50:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
